MRI R2* Relaxometry as the Preferred Tool for Detecting and Managing Iron Overload

Diagnostic Superiority of MRI R2*

MRI with confounder‑corrected R2*‑based relaxometry provides the most accurate detection and quantification of iron overload in both the liver and pancreas, outperforming all other modalities. [1][2]
MRI is now the universally accepted non‑invasive diagnostic test for iron overload, eliminating the need for liver biopsy in the majority of clinical scenarios. [1][2]
The technique exploits iron‑induced acceleration of transverse proton relaxation, producing tissue “darkening” that is directly proportional to iron concentration. 1

R2* sequences are the best‑validated method for quantifying tissue iron concentrations, supported by multiple high‑quality studies. [3][4][5][6]
Confounder‑corrected R2*‑based liver iron concentration (LIC) measurement at both 1.5 T and 3 T offers the most practical approach with the strongest level of evidence for accurate and reproducible quantification. [1][2]

A single MRI examination can simultaneously evaluate iron deposition in the liver, spleen, pancreas, heart, and brain, facilitating comprehensive disease staging. [3][4][5][6]
Distinct patterns of organ iron distribution aid differential diagnosis: early hereditary hemochromatosis typically shows predominant hepatic iron with minimal splenic involvement, whereas ferroportin disease and transfusional overload display increased splenic iron. [3][4]6

Serum ferritin and transferrin saturation are sensitive but lack specificity for iron overload, limiting their diagnostic reliability. [2][3]4
Ferritin is an acute‑phase reactant that rises in inflammation and infection, rendering it unreliable as a standalone test. [2][3]
Isolated serum iron parameters are frequently insufficient to confirm iron overload. [3][4][5][6]

Ultrasound and computed tomography provide little quantitative information on liver iron content and are not recommended for iron overload assessment. [1][2]

Liver biopsy is not recommended for diagnosing hepatic iron overload when MRI is available, given its superior accuracy and non‑invasiveness. [3][5]6
Biopsy is now reserved mainly for evaluating liver fibrosis in patients with markedly elevated ferritin (e.g., >1,000 µg/L) or abnormal liver enzymes. [3][5]6

Hepatic R2* quantification serves as a surrogate marker of total body iron stores because liver iron concentration correlates linearly with total iron burden. [1][2][3][4]6
Elevated hepatic R2* predicts a higher risk of organ damage, guiding risk stratification and monitoring. [3][4]6
Baseline hepatic R2* values forecast the number of therapeutic phlebotomies required for iron removal. [3][4]6
R2* measurement is essential for initiating and adjusting chelation or phlebotomy therapy, ensuring treatment efficacy. [1][2]